What the FDA labels say about taking them together
Hydroxyurea and olutasidenib
Olutasidenib's FDA label of November 5, 2025 names hydroxyurea in its warnings and precautions section; the hydroxyurea labels PlainMeds reads (3) do not name olutasidenib.
Check it at the source: the hydroxyurea FDA label on DailyMed (effective September 15, 2025, Waylis Therapeutics LLC); the olutasidenib FDA label on DailyMed (effective November 5, 2025, Rigel Pharmaceuticals, Inc.).
What does the hydroxyurea label say about olutasidenib?
Hydroxyurea's label (effective September 15, 2025) and its 2 other brand-application labels do not name olutasidenib in these sections. A label lists what its studies and reports found; it is not a complete list.
Source: FDA drug label (HYDREA), Waylis Therapeutics LLC, effective September 15, 2025 (SPL set 8d41152f-a98a-4abc-afdf-a909012434a0), via openFDA; the full label on DailyMed
What does the olutasidenib label say about hydroxyurea?
Olutasidenib label, warnings and precautionsDifferentiation syndrome may recur with premature discontinuation of corticosteroids and/or hydroxyurea treatment.
Source: FDA drug label (REZLIDHIA), Rigel Pharmaceuticals, Inc., effective November 5, 2025 (SPL set 4a0c7c8b-b95f-455d-9600-b7351e4397fe), via openFDA; the full label on DailyMed
These are the labels' own sentences. PlainMeds does not grade interactions; a pharmacist or prescriber can say what they mean for one person's medicines.
Both medicines on the record
| Hydroxyurea | Olutasidenib | |
|---|---|---|
| Labeled for | Leukemia, lymphoma and myeloma | Leukemia, lymphoma and myeloma |
| Boxed warning | No | Yes |
| Pharmacy cost (NADAC) | $0.184 per capsule 500 mg capsule | n/a |
| Shortage now | No current entry | No current entry |
Source: FDA NDC Directory, CMS NADAC of October 7, 2026 and the FDA Drug Shortage Database (FDA files October 8, 2026)
What next?
- Check more medicines together
- up to five at once